HONG KONG – Jiangsu, China-based Atom Bioscience and Pharmaceutical Co. Ltd. plans to advance its lead drug candidate – ABP-601 to treat hyperuricemia and gout – into clinical trials in the U.S. after completing a ¥80 million (US$12.3 million) series A round of financing from an undisclosed angel investor.
HONG KONG – Xian Janssen Pharmaceutical Ltd. has launched Simponi (golimumab injection), making it the first once-monthly self-injectable anti-TNF biologic for patients with active ankylosing spondylitis (AS) in China.
HONG KONG – Xian Janssen Pharmaceutical Ltd. has launched Simponi (golimumab injection), making it the first once-monthly self-injectable anti-TNF biologic for patients with active ankylosing spondylitis (AS) in China.
HONG KONG – Chinese biotech firm Shanghai Henlius Biotech Inc. is taking its PD-L1 antibody known as HLX-20 to Australia to enter a phase I trial for the treatment of advanced solid tumors. The approval from the Australian authorities came six months after Henlius filed the investigational new drug (IND) application for HLX-20 to the China Drug Administration (CDA), and the trial will be the company's first in Australia.
HONG KONG – Hangzhou, China-based Ascletis Pharma Inc. said its core product, Ganovo (danoprevir) for the treatment of viral hepatitis C, recently approved by the China Drug Administration (CDA), is poised to be a blockbuster for the startup.
HONG KONG – Hangzhou, China-based Ascletis Pharma Inc. said its core product, Ganovo (danoprevir) for the treatment of viral hepatitis C, recently approved by the China Drug Administration (CDA), is poised to be a blockbuster for the startup.
HONG KONG – Chinese biotech firm Shanghai Henlius Biotech Inc. is taking its PD-L1 antibody known as HLX-20 to Australia to enter a phase I trial for the treatment of advanced solid tumors. The approval from the Australian authorities came six months after Henlius filed the investigational new drug (IND) application for HLX-20 to the China Drug Administration (CDA), and the trial will be the company's first in Australia.
HONG KONG – Tetraphase Pharmaceuticals Inc., of Watertown, Mass., said its Chinese partner, Everest Medicines Ltd., has filed an application with Chinese regulators to initiate the phase III trial of its lead product eravacycline in complicated intra-abdominal infections (cIAIs).
